Key points from article :
A Berlin-based startup is pushing the boundaries of life and death. Tomorrow.Bio, Europe’s first cryonics lab, has secured €5 million in seed funding to expand into the United States and further invest in its research and development. The company was co-founded in 2020 by Dr Emil Kendziorra, a former cancer researcher, and Fernando Azevedo Pinheiro. Their goal: to give people another shot at life by preserving bodies at ultra-low temperatures after legal death, with the hope of future revival when medicine has advanced enough to cure diseases like cancer.
The new funding round was co-led by investors Blast.Club and Truventuro. Tomorrow.Bio currently operates in partnership with the European Biostasis Foundation in Switzerland, where bodies are cryopreserved in large vacuum-insulated containers filled with liquid nitrogen. The process begins shortly after legal death, with specialised ambulances and trained teams initiating cooling and replacing bodily fluids with a cryoprotective solution that prevents ice damage.
So far, the company has preserved 20 humans and 10 pets, with more than 800 people already signed up and total contracts valued over €160 million. The company now plans to establish operations in New York, California, and Florida, making it the first cryonics company with immediate-response teams in both Europe and the U.S.
